Base de datos : MEDLINE Búsqueda : Condiloma and Acuminado [Palabras] Referencias encontradas : 4356 [refinar] Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 436

va a la página

1 / 4356

MEDLINE

selecciona para imprimir Fotocopia Texto completo

[PMID]: 23199959 [Au] Autor: Canfell K; Chesson H; Kulasingam SL; Berkhof J; Diaz M; Kim JJ [Ad] Dirección: Cancer Epidemiology Research Unit, Cancer Council NSW, Sydney, Australia. karenc@nswcc.org.au [Ti] Título: Modeling preventative strategies against human papillomavirus-related disease in developed countries. [So] Fuente: Vaccine;30 Suppl 5:F157-67, 2012 Nov 20. [Is] ISSN: 1873-2518 [Cp] País de publicación: Netherlands [La] Idioma: eng [Ab] Resumen: Over the last 5 years, prophylactic vaccination against human papillomavirus (HPV) in pre-adolescent females has been introduced in most developed countries, supported by modeled evaluations that have almost universally found vaccination of pre-adolescent females to be cost-effective. Studies to date suggest that vaccination of pre-adolescent males may also be cost-effective at a cost per vaccinated individual of ~US$400-500 if vaccination coverage in females cannot be increased above ~50%; but if it is possible, increasing coverage in females appears to be a better return on investment. Comparative evaluation of the quadrivalent (HPV16,18,6,11) and bivalent (HPV16,18) vaccines centers around the potential trade-off between protection against anogenital warts and vaccine-specific levels of cross-protection against infections not targeted by the vaccines. Future evaluations will also need to consider the cost-effectiveness of a next generation nonavalent vaccine designed to protect against ~90% of cervical cancers. The timing of the effect of vaccination on cervical screening programs will be country-specific and will depend on vaccination catch-up age range and coverage and the age at which screening starts. Initial evaluations suggest that if screening remains unchanged, it will be less cost-effective in vaccinated compared to unvaccinated women but, in the context of current vaccines, will remain an important prevention method. Comprehensive evaluation of new approaches to screening will need to consider the population-level effects of vaccination over time. New screening strategies of particular interest include delaying the start age of screening, increasing the screening interval and switching to primary HPV screening. Future evaluations of screening will also need to focus on the effects of disparities in screening and vaccination uptake, the potential effects of vaccination on screening participation, and the effects of imperfect compliance with screening recommendations. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012. [Mh] Términos MeSH primario: Neoplasias de los Genitales Femeninos/prevención & control Neoplasias de los Genitales Masculinos/prevención & control Infecciones por Papillomavirus/complicaciones Infecciones por Papillomavirus/prevención & control Vacunas contra Papillomavirus/administración & dosificación [Mh] Términos MeSH secundario: Condiloma Acuminado/epidemiología Condiloma Acuminado/prevención & control Análisis Costo-Beneficio Países Desarrollados Femenino Neoplasias de los Genitales Femeninos/epidemiología Neoplasias de los Genitales Masculinos/epidemiología Humanos Masculino Tamizaje Masivo/economía Tamizaje Masivo/métodos Infecciones por Papillomavirus/epidemiología Vacunación/economía Vacunación/utilización Virología/economía Virología/métodos [Pt] Tipo de publicación: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW [Nm] Nombre de substancia: 0 (Papillomavirus Vaccines) [Em] Mes de ingreso: 1305 [Sb] Subgrupo de revista: IM [Da] Fecha de ingreso para procesamiento: 121203 [St] Status: MEDLINE

2 / 4356

MEDLINE

selecciona para imprimir Fotocopia Texto completo

[PMID]: 23199956 [Au] Autor: Schiller JT; Castellsagué X; Garland SM [Ad] Dirección: Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. schillej@mail.nih.gov [Ti] Título: A review of clinical trials of human papillomavirus prophylactic vaccines. [So] Fuente: Vaccine;30 Suppl 5:F123-38, 2012 Nov 20. [Is] ISSN: 1873-2518 [Cp] País de publicación: Netherlands [La] Idioma: eng [Ab] Resumen: End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV) virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct vaccines were evaluated, Gardasil(®) (Merck & Co., Whitehouse Station, NJ USA) a quadrivalent vaccine containing VLPs of types 6, 11, 16 and 18 and Cervarix(®) (GlaxoSmithKline Biologicals, Rixensart, Belgium), a bivalent vaccine containing VLPs of types 16 and 18. Both vaccines exhibited excellent safety and immunogenicity profiles. The vaccines also demonstrated remarkably high and similar efficacy against the vaccine-targeted types for a range of cervical endpoints from persistent infection to cervical intraepithelial neoplasia grade 3 (CIN3) in women naïve to the corresponding type at the time of vaccination. However, protection from incident infection or disease from non-vaccine types was restricted, and the vaccines had no effect on prevalent infection or disease. Gardasil(®) also demonstrated strong protection against genital warts and vulvar/vaginal neoplasia associated with the vaccine types. In other trials, Gardasil(®) protected mid-adult women from incident infection and CIN caused by the vaccine types and protected men for incident infection, genital warts and anal intraepithelial neoplasia by the vaccine types. Cervarix(®) protected against vaccine-targeted anal infections in women in an end of study evaluation. For practical reasons, efficacy studies have not been conducted in the primary target populations of current vaccination programs, adolescent girls and boys. However, immunogenicity bridging studies demonstrating excellent safety and strong immune responses in adolescence, coupled with the documentation of durable antibody responses and protection in young adults, leads to an optimistic projection of the effectiveness of the vaccines in adolescent vaccination programs. Taken together, the excellent clinical trial results strongly support the potential of the vaccines as high value public health interventions and justify their widespread implementation to prevent anogenital HPV infections and their associated neoplasia. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012. [Mh] Términos MeSH primario: Infecciones por Papillomavirus/prevención & control Vacunas contra Papillomavirus/administración & dosificación Vacunas contra Papillomavirus/inmunología [Mh] Términos MeSH secundario: Neoplasias del Ano/prevención & control Neoplasias del Ano/virología Ensayos Clínicos Fase III como Asunto Condiloma Acuminado/prevención & control Condiloma Acuminado/virología Femenino Humanos Masculino Infecciones por Papillomavirus/complicaciones Vacunas contra Papillomavirus/efectos adversos Neoplasias del Cuello Uterino/prevención & control Neoplasias del Cuello Uterino/virología Vacunas de Partículas Similares a Virus/administración & dosificación Vacunas de Partículas Similares a Virus/efectos adversos Vacunas de Partículas Similares a Virus/inmunología Neoplasias Vaginales/prevención & control Neoplasias Vaginales/virología Neoplasias de la Vulva/prevención & control Neoplasias de la Vulva/virología [Pt] Tipo de publicación: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW [Nm] Nombre de substancia: 0 (Papillomavirus Vaccines); 0 (Vaccines, Virus-Like Particle); 0 (human papillomavirus vaccine L1, type 6,11,16,18); 0 (human papillomavirus vaccine, L1 type 16, 18) [Em] Mes de ingreso: 1305 [Sb] Subgrupo de revista: IM [Da] Fecha de ingreso para procesamiento: 121203 [St] Status: MEDLINE

3 / 4356

MEDLINE

selecciona para imprimir Fotocopia Texto completo

[PMID]: 23199955 [Au] Autor: Forman D; de Martel C; Lacey CJ; Soerjomataram I; Lortet-Tieulent J; Bruni L; Vignat J; Ferlay J; Bray F; Plummer M; Franceschi S [Ad] Dirección: Section of Cancer Information, International Agency for Research on Cancer, Lyon, France. formand@iarc.fr [Ti] Título: Global burden of human papillomavirus and related diseases. [So] Fuente: Vaccine;30 Suppl 5:F12-23, 2012 Nov 20. [Is] ISSN: 1873-2518 [Cp] País de publicación: Netherlands [La] Idioma: eng [Ab] Resumen: The worldwide prevalence of infection with human papillomavirus (HPV) in women without cervical abnormalities is 11-12% with higher rates in sub-Saharan Africa (24%), Eastern Europe (21%) and Latin America (16%). The two most prevalent types are HPV16 (3.2%) and HPV18 (1.4%). Prevalence increases in women with cervical pathology in proportion to the severity of the lesion reaching around 90% in women with grade 3 cervical intraepithelial neoplasia and invasive cancer. HPV infection has been identified as a definite human carcinogen for six types of cancer: cervix, penis, vulva, vagina, anus and oropharynx (including the base of the tongue and tonsils). Estimates of the incidence of these cancers for 2008 due to HPV infection have been calculated globally. Of the estimated 12.7 million cancers occurring in 2008, 610,000 (Population Attributable Fraction [PAF]=4.8%) could be attributed to HPV infection. The PAF varies substantially by geographic region and level of development, increasing to 6.9% in less developed regions of the world, 14.2% in sub-Saharan Africa and 15.5% in India, compared with 2.1% in more developed regions, 1.6% in Northern America and 1.2% in Australia/New Zealand. Cervical cancer, for which the PAF is estimated to be 100%, accounted for 530,000 (86.9%) of the HPV attributable cases with the other five cancer types accounting for the residual 80,000 cancers. Cervical cancer is the third most common female malignancy and shows a strong association with level of development, rates being at least four-fold higher in countries defined within the low ranking of the Human Development Index (HDI) compared with those in the very high category. Similar disparities are evident for 5-year survival-less than 20% in low HDI countries and more than 65% in very high countries. There are five-fold or greater differences in incidence between world regions. In those countries for which reliable temporal data are available, incidence rates appear to be consistently declining by approximately 2% per annum. There is, however, a lack of information from low HDI countries where screening is less likely to have been successfully implemented. Estimates of the projected incidence of cervical cancer in 2030, based solely on demographic factors, indicate a 2% increase in the global burden of cervical cancer, i.e., in balance with the current rate of decline. Due to the relative small numbers involved, it is difficult to discern temporal trends for the other cancers associated with HPV infection. Genital warts represent a sexually transmitted benign condition caused by HPV infection, especially HPV6 and HPV11. Reliable surveillance figures are difficult to obtain but data from developed countries indicate an annual incidence of 0.1 to 0.2% with a peak occurring at teenage and young adult ages. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012. [Mh] Términos MeSH primario: Neoplasias del Ano/epidemiología Condiloma Acuminado/epidemiología Infecciones por Papillomavirus/epidemiología Neoplasias del Pene/epidemiología Neoplasias Faríngeas/epidemiología Neoplasias del Cuello Uterino/epidemiología Neoplasias de la Vulva/epidemiología [Mh] Términos MeSH secundario: Neoplasias del Ano/virología Condiloma Acuminado/virología Femenino Humanos Incidencia Masculino Papillomaviridae/clasificación Papillomaviridae/aislamiento & purificación Papillomaviridae/patogenicidad Infecciones por Papillomavirus/complicaciones Neoplasias del Pene/virología Neoplasias Faríngeas/virología Prevalencia Neoplasias del Cuello Uterino/virología Neoplasias de la Vulva/virología Salud Mundial [Pt] Tipo de publicación: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW [Em] Mes de ingreso: 1305 [Sb] Subgrupo de revista: IM [Da] Fecha de ingreso para procesamiento: 121203 [St] Status: MEDLINE

4 / 4356

MEDLINE

selecciona para imprimir Fotocopia PubMed Central Texto completo Texto completo

[PMID]: 22634446 [Au] Autor: Jardine D; Lu J; Pang J; Palmer C; Tu Q; Chuah J; Frazer IH [Ad] Dirección: Princess Alexandra Sexual Health, Princess Alexandra Hospital, Brisbane, QLD, Australia. [Ti] Título: A randomized trial of immunotherapy for persistent genital warts. [So] Fuente: Hum Vaccin Immunother;8(5):623-9, 2012 May. [Is] ISSN: 2164-554X [Cp] País de publicación: United States [La] Idioma: eng [Ab] Resumen: AIM: To determine whether immunotherapy with HPV6 L1 virus like particles (VLPs) without adjuvant (VLP immunotherapy) reduces recurrence of genital warts following destructive therapy. TRIAL DESIGN: A randomized placebo controlled blinded study of treatment of recurrent genital warts amenable to destructive therapy, conducted independently in Australia and China. METHODS: Patients received conventional destructive therapy of all evident warts together with intramuscular administration of 1 µg, 5 µg or 25 µg of VLP immunotherapy, or of placebo immunotherapy (0.9% NaCl), as immunotherapy at week 0 and week 4. Primary outcome, assessed at week 8, was recurrence of visible warts. RESULTS: Of 33 protocol compliant Brisbane recipients of placebo immunotherapy, 11 were disease free at two months, and a further 9 demonstrated reduction of > 50% in total wart area. Wart area reduction following destructive treatment correlated with prior duration of disease. Among 102 protocol compliant Brisbane recipients of VLP immunotherapy, disease reduction was significantly greater than among the placebo immunotherapy (50% ± s.e.m. 7%) recipients for subjects receiving 5 µg or 25 µg of VLP immunotherapy/dose (71% ± s.e.m. 7%) but not for those receiving 1 µg VLP immunotherapy/dose (42% ± 7%). Of 52 protocol compliant placebo immunotherapy recipients in Wenzhou, 37 were disease free at two months, and a further 8 had > 50% disease reduction. Prior disease duration was much shorter in Wenzhou subject (8.1 ± 1.1 mo) than in Brisbane subjects (53.7 ± 5.5 mo). No significant reduction in mean wart area was observed for the 168 Wenzhou protocol compliant subjects who also received VLP immunotherapy. CONCLUSIONS: This study confirms the findings in a previous open label trial that administration of VLP immunotherapy may assist in clearance of recurrent genital warts in patients for whom destructive therapy is unsuccessful and that unsuccessful destructive therapy is more common with increasing prior disease duration. [Mh] Términos MeSH primario: Proteínas del Cápside/inmunología Condiloma Acuminado/terapia Inmunoterapia/métodos Proteínas Oncogénicas Virales/inmunología Vacunas contra Papillomavirus/inmunología [Mh] Términos MeSH secundario: Adolescente Adulto Australia Proteínas del Cápside/administración & dosificación China Enfermedad Crónica Condiloma Acuminado/cirugía Método Doble Ciego Femenino Papillomavirus Humano 16/inmunología Humanos Masculino Proteínas Oncogénicas Virales/administración & dosificación Vacunas contra Papillomavirus/administración & dosificación Placebos/administración & dosificación Recurrencia/prevención & control Resultado del Tratamiento Vacunas de Virosoma/administración & dosificación Vacunas de Virosoma/inmunología Adulto Joven [Pt] Tipo de publicación: JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Nombre de substancia: 0 (Capsid Proteins); 0 (L1 protein, Human papillomavirus type 16); 0 (Oncogene Proteins, Viral); 0 (Papillomavirus Vaccines); 0 (Placebos); 0 (Vaccines, Virosome) [Em] Mes de ingreso: 1301 [Cu] Fecha actualización por clase: 130502 [Lr] Fecha última revisión: 130502 [Sb] Subgrupo de revista: IM [Da] Fecha de ingreso para procesamiento: 120822 [St] Status: MEDLINE [do] DOI: 10.4161/hv.19319

5 / 4356

MEDLINE

selecciona para imprimir Fotocopia Texto completo

[PMID]: 23116916 [Au] Autor: Intlekofer KA; Cunningham MJ; Caplan AL [Ad] Dirección: Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, USA. [Ti] Título: The HPV vaccine controversy. [So] Fuente: Virtual Mentor;14(1):39-49, 2012. [Is] ISSN: 1937-7010 [Cp] País de publicación: United States [La] Idioma: eng [Mh] Términos MeSH primario: Condiloma Acuminado/prevención & control Infecciones por Papillomavirus/prevención & control Vacunas contra Papillomavirus/administración & dosificación Vacunas contra Papillomavirus/efectos adversos Aceptación de la Atención de Salud Neoplasias del Cuello Uterino/prevención & control [Mh] Términos MeSH secundario: Adolescente Adulto Actitud del Personal de Salud Niño Condiloma Acuminado/epidemiología Estudios Transversales Aprobación de Drogas Femenino Educación en Salud/ética Humanos Masculino Vacunación Masiva/ética Infecciones por Papillomavirus/epidemiología Infecciones por Papillomavirus/transmisión Estados Unidos United States Food and Drug Administration Neoplasias del Cuello Uterino/epidemiología Adulto Joven [Pt] Tipo de publicación: JOURNAL ARTICLE [Nm] Nombre de substancia: 0 (Papillomavirus Vaccines); 0 (human papillomavirus vaccine L1, type 6,11,16,18) [Em] Mes de ingreso: 1305 [Sb] Subgrupo de revista: IM [Da] Fecha de ingreso para procesamiento: 121102 [St] Status: MEDLINE

6 / 4356

MEDLINE

selecciona para imprimir Fotocopia Texto completo

[PMID]: 22470190 [Au] Autor: Wronski K; Bocian R [Ad] Dirección: Department of General and Vascular Surgery, Mikolaj Pirogow Regional Specialist Hospital, Lodz, Poland, the European Community. konradwronski@wp.pl [Ti] Título:  Surgical excision of extensive anal condylomata is a safe operation without risk of anal stenosis. [So] Fuente: Postepy Hig Med Dosw (Online);66:153-7, 2012. [Is] ISSN: 1732-2693 [Cp] País de publicación: Poland [La] Idioma: eng [Ab] Resumen: INTRODUCTION: Anal condylomata acuminata was a well-known disease in ancient times but in recent years there has been a rapidly increasing number of people who suffer from this disease. The main cause of this disease is infection of human papilloma virus (HPV) which occurs through sexual contact. Currently there are three different ways to treat anal condylomata. Small changes of anal condylomata can be treated with local therapeutic agents, but the best results of treatment of extensive changes are obtained by surgical techniques. MATERIAL/METHODS: The study group consisted of 30 patients with diagnosed extensive anal condylomata who underwent surgery in Mikolaj Pirogow High Specialized Hospital in Lodz. The survey was conducted from 2007 to 2011. Patients had been directed to the surgical ward by general surgeons and practitioners, proctologists and urologists. The diagnosis was made after proctological assessment in the knee-chest position. RESULTS: All patients underwent surgery and had complete macroscopic electroexcision of anal condylomata. In the research group there was no mortality. Postoperative complications occurred in 4 (13.3%) patients--postoperative bleeding. Strong pain was present in 14 (46.7%) patients but only in the postoperative period. During postoperative follow-up there was no observed infection in the anal region or recurrence of disease. In the operated group there were no observed cosmetic deformations of the anus and/or the anal canal, narrow anal canal or functional fecal incontinence symptoms. CONCLUSIONS: Surgical treatment of anal condylomata is an effective and safe method for the patient. In our research there were no serious postoperative complications or recurrence of the disease during the follow-up period. [Mh] Términos MeSH primario: Enfermedades del Ano/cirugía Condiloma Acuminado/cirugía Electrocirugia Infecciones por Papillomavirus/cirugía [Mh] Términos MeSH secundario: Adulto Enfermedades del Ano/etiología Enfermedades del Ano/patología Enfermedades del Ano/prevención & control Cicatriz Hipertrófica/etiología Condiloma Acuminado/economía Condiloma Acuminado/patología Constricción Patológica/etiología Constricción Patológica/prevención & control Electrocirugia/efectos adversos Electrocirugia/economía Costos de la Atención en Salud Humanos Obstrucción Intestinal/etiología Obstrucción Intestinal/prevención & control Masculino Infecciones por Papillomavirus/economía Infecciones por Papillomavirus/patología Polonia Complicaciones Postoperatorias/diagnóstico Complicaciones Postoperatorias/etiología Complicaciones Postoperatorias/prevención & control Recurrencia/prevención & control Resultado del Tratamiento [Pt] Tipo de publicación: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Em] Mes de ingreso: 1305 [Sb] Subgrupo de revista: IM [Da] Fecha de ingreso para procesamiento: 120403 [St] Status: MEDLINE [do] DOI: 10.5604/17322693.987538

7 / 4356

MEDLINE

selecciona para imprimir Fotocopia

[PMID]: 23135094 [Au] Autor: Rosen T [Ad] Dirección: Department of Dermatology, Baylor College of Medicine, Houston, TX, USA. vampireted@aol.com [Ti] Título: Green tea catechins: biologic properties, proposed mechanisms of action, and clinical implications. [So] Fuente: J Drugs Dermatol;11(11):e55-60, 2012 Nov. [Is] ISSN: 1545-9616 [Cp] País de publicación: United States [La] Idioma: eng [Ab] Resumen: Botanical products, including and especially green tea leaves, have a wide range of both reputed and demonstrated health benefits and have been used medicinally for thousands of years. This paper focuses on green tea catechins, principally reviewing their known biologic properties and potential mechanisms of action (MOAs). The primary objective is to discuss the proposed antiviral, antiproliferative, and immunostimulatory activity of catechins based on strong evidence from in vitro and in vivo studies conducted to date, including two preclinical in vitro studies with sinecatechins, a proprietary mixture of catechins. This review also discusses the clinical implications of catechins for the treatment of external genital and perianal warts (EGWs) and other conditions caused by human papillomavirus (HPV). While the MOA of catechins in the treatment of EGWs and other HPV-related conditions may be related to or associated with postulated or proven antiviral and immunostimulatory activity, the precise clinical significance of the various in vitro findings remains largely unknown. [Mh] Términos MeSH primario: Catequina/uso terapéutico Extractos Vegetales/uso terapéutico Té/química [Mh] Términos MeSH secundario: Adyuvantes Inmunológicos/aislamiento & purificación Adyuvantes Inmunológicos/farmacología Adyuvantes Inmunológicos/uso terapéutico Animales Antivirales/uso terapéutico Catequina/aislamiento & purificación Catequina/farmacología Proliferación de la Célula/efectos de drogas Condiloma Acuminado/quimioterapia Humanos Infecciones por Papillomavirus/quimioterapia Extractos Vegetales/farmacología Hojas de la Planta [Pt] Tipo de publicación: JOURNAL ARTICLE; REVIEW [Nm] Nombre de substancia: 0 (Adjuvants, Immunologic); 0 (Antiviral Agents); 0 (Plant Extracts); 0 (Tea); 154-23-4 (Catechin) [Em] Mes de ingreso: 1305 [Sb] Subgrupo de revista: IM [Da] Fecha de ingreso para procesamiento: 121108 [St] Status: MEDLINE

8 / 4356

MEDLINE

selecciona para imprimir Fotocopia Texto completo

[PMID]: 22718097 [Au] Autor: Jamshidi M; Shekari M; Nejatizadeh AA; Malekzadeh K; Baghershiroodi M; Davudian P; Dehghan F; Jamshidi F [Ad] Dirección: Infections Research Center, Hormozgan University of Medical Sciences, Bandar-Abbas, Iran. [Ti] Título: The impact of human papillomavirus (HPV) types 6, 11 in women with genital warts. [So] Fuente: Arch Gynecol Obstet;286(5):1261-7, 2012 Nov. [Is] ISSN: 1432-0711 [Cp] País de publicación: Germany [La] Idioma: eng [Ab] Resumen: OBJECTIVE: Human papillomaviruses (HPV) are etiologically associated with the development of virtually all genital warts. HPV-6 and HPV-11 are the most commonly detected HPV genotypes, but at least 20 other HPV genotypes have occasionally been found in genital wart tissue specimens. STUDY DESIGN: The aim of this study was to determine from 100 genital wart tissue specimens collected from female patients using multiplex gap-PCR technique the prevalence of various genital HPV among women with HPV genital warts in south of Iran. 100 genital wart tissue specimens were tested for the presence of HPV PG5/PG6 and also for HPV type using polymerase chain reaction (PCR). RESULTS: Based on the collected data, 73 (73 %) samples were detected positive for HPV DNA and 23 (23 %) samples out of 100 samples were detected negative for HPV DNA. 49 (49 %) and 67 (67 %) of patients were detected positive for HPV type 6 and 11, respectively. There was a significant association between marital status and HPV genotype 6 (OR = 0.51, 95 % CI = 0.37-0.70, P = 0.01). Nevertheless, no significant association was found between marriage and HPV genotype 11 (OR = 0.85, 95 % CI = 0.58-1, 24, P = 0.7). Similarly, this result was demonstrated, in combined marriage and HPV-general (OR = 0.80, 95 % CI = 0.62-0.05, P = 0.4). CONCLUSION: Concerning the prevalence of HPV in our study, determination of genital HPV prevalence and multiple infections among the normal population of women of Hormozgan Province is recommended. [Mh] Términos MeSH primario: Condiloma Acuminado/epidemiología Condiloma Acuminado/virología Papillomavirus Humano 11 Papillomavirus Humano 6 [Mh] Términos MeSH secundario: Adulto Intervalos de Confianza ADN Viral/metabolismo Femenino Genotipo Papillomavirus Humano 11/genética Papillomavirus Humano 6/genética Humanos Irán/epidemiología Estado Civil Oportunidad Relativa Prevalencia Adulto Joven [Pt] Tipo de publicación: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Nombre de substancia: 0 (DNA, Viral) [Em] Mes de ingreso: 1304 [Sb] Subgrupo de revista: IM [Da] Fecha de ingreso para procesamiento: 121016 [St] Status: MEDLINE [do] DOI: 10.1007/s00404-012-2416-1

9 / 4356

MEDLINE

selecciona para imprimir Fotocopia

[PMID]: 22944184 [Au] Autor: Li XC; Zhu L; Gu Y; Jin HM; Wang CY; Xu T; Lang JH [Ad] Dirección: Department of Obstetrics & Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, China. [Ti] Título: [Outcome prediction of single-period CO(2) laser therapy for vulvar condylomata acuminate]. [So] Fuente: Zhonghua Yi Xue Za Zhi;92(25):1759-62, 2012 Jul 3. [Is] ISSN: 0376-2491 [Cp] País de publicación: China [La] Idioma: chi [Ab] Resumen: OBJECTIVE: To evaluate the outcome of CO(2) laser treatment as primary therapy for vulvar condylomata acuminate and examine the risk factors and prediction model of single-period CO(2) laser treatment. METHODS: Between March 2009 and December 2010, a multicenter prospective study was conducted at three 3A hospitals of China (Peking Union Medical College Hospital, Zhejiang Women's Health Hospital & Tongji Hospital). All enrolled patients of vulvar condylomata acuminata received CO(2) laser vaporization as the primary therapy and had return visits at 1, 3 and 6 months individually after treatment. Therapeutic recurrence and side effects were recorded. Logistic regression was used to analyze the associations between demographic or clinical characteristics and the outcome of single-period CO(2) laser treatment and a prediction model was established subsequently. The optimal cutoff value of model was evaluated by area under the receiver operating characteristic curve (AUC ROC). RESULTS: A total of 160 patients completed a 6-month follow-up with a loss rate of 9.1% (16/176). And 131 patients (82%) were cured after the single-period CO(2) laser therapy with a total recovery rate of 94% (150/160). Side effects occurred in 50 (31%) patients with a complete self-recovery within 6 months. The most common side effects were local ulceration, pain and edema. No severe side effect was present. Large area of lesion (>8 cm(2)), vagina involved and unemployment were associated with the failure of single-period treatment while pain symptom was a protective factor of effectiveness. Age, marital status, symptom-free and vaginal involvement were not related with outcome. A prediction model was established as follows: Logit (P(0)) = -1.511+1.573X(1)+1.679X(2)+3.254X(3)-1.685X(4) (X(1)-X(4) representing area of lesion > 8 cm(2), vaginal involvement, unemployment and pain symptom respectively). The optimal cutoff value of P(0) was 0.35 with AUC ROC of 0.816 (P < 0.01). The sensitivity, specificity, positive predictive value and negative predictive value of model were 58.6%, 91.6%, 60.7% and 90.9% respectively. CONCLUSION: CO(2) laser is effective and safe therapy for vulvar condylomata acuminata. A prediction model has been proposed to predict the outcome of single-period CO(2) laser therapy in initially diagnosed patients. It may guide clinical decision-making. [Mh] Términos MeSH primario: Condiloma Acuminado/cirugía Terapia por Láser Enfermedades de la Vulva/cirugía [Mh] Términos MeSH secundario: Adolescente Adulto Anciano Área Bajo la Curva Femenino Humanos Modelos Logísticos Mediana Edad Pronóstico Estudios Prospectivos Curva ROC Resultado del Tratamiento Adulto Joven [Pt] Tipo de publicación: ENGLISH ABSTRACT; JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S. [Em] Mes de ingreso: 1304 [Sb] Subgrupo de revista: IM [Da] Fecha de ingreso para procesamiento: 120904 [St] Status: MEDLINE

10 / 4356

MEDLINE

selecciona para imprimir Fotocopia

[PMID]: 23402241 [Au] Autor: Kiellberg Larsen H; Kofoed K; Sand C [Ad] Dirección: Dermato-venerologisk Afdeling D, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 København NV, Denmark. hellekl@dadlnet.dk [Ti] Título: [The disease burden of human papillomavirus in men is substantial and can potentially be prevented]. [Ti] Título: Den HPV-relaterede sygdomsbyrde hos mænd er stor og kan forebygges.. [So] Fuente: Ugeskr Laeger;175(6):349-53, 2013 Feb 4. [Is] ISSN: 1603-6824 [Cp] País de publicación: Denmark [La] Idioma: dan [Ab] Resumen: Human papillomavirus (HPV) is a highly prevalent sexually transmitted infection. High-risk HPV causes penile cancer and a substantial proportion of oropharyngeal and anal malignancy in men. Low-risk types of HPV cause anogenital warts. The incidence of oropharyngeal and anal cancers is increasing in Denmark. Prevention of penile, anal and oropharyngeal cancers and anogenital warts represents potential benefits of the HPV vaccine; and vaccination of men is now recommended by the Australian and the North American health authorities. Thus, we recommend that the Danish HPV vaccination program should include men. [Mh] Términos MeSH primario: Infecciones por Papillomavirus/complicaciones [Mh] Términos MeSH secundario: Adolescente Neoplasias del Ano/epidemiología Neoplasias del Ano/prevención & control Neoplasias del Ano/virología Tumor de Buschke-Lowenstein/patología Condiloma Acuminado/epidemiología Condiloma Acuminado/prevención & control Condiloma Acuminado/virología Costo de Enfermedad Dinamarca/epidemiología Femenino Homosexualidad Masculina Humanos Programas de Inmunización Masculino Neoplasias Orofaríngeas/epidemiología Neoplasias Orofaríngeas/prevención & control Neoplasias Orofaríngeas/virología Infecciones por Papillomavirus/epidemiología Infecciones por Papillomavirus/prevención & control Vacunas contra Papillomavirus Neoplasias del Pene/epidemiología Neoplasias del Pene/patología Neoplasias del Pene/prevención & control Neoplasias del Pene/virología Adulto Joven [Pt] Tipo de publicación: ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW [Nm] Nombre de substancia: 0 (Papillomavirus Vaccines) [Em] Mes de ingreso: 1304 [Sb] Subgrupo de revista: IM [Da] Fecha de ingreso para procesamiento: 130213 [St] Status: MEDLINE

---

página 1 de 436

va a la página

Refinar la búsqueda

Base de datos : MEDLINE

Formulario avanzado

		Buscar	en el campo
1			PalabrasDescriptor de asuntoDescriptor de asunto primarioLímitesAutorPalabras del títuloPalabras del resumenIdiomaPaís de publicaciónNombre de substanciaNombre personal como asuntoRevistaAsunto de RevistaISSNTipo de publicaciónIdentificador únicoMes de ingresoAño de publicaciónTexto completoActualización por claseCategoria DeCSCategoria DeCS explodidaCategoria CIE-10SubSetsPaís de AfiliaciónAfiliación
2	and or and not		PalabrasDescriptor de asuntoDescriptor de asunto primarioLímitesAutorPalabras del títuloPalabras del resumenIdiomaPaís de publicaciónNombre de substanciaNombre personal como asuntoRevistaAsunto de RevistaISSNTipo de publicaciónIdentificador únicoMes de ingresoAño de publicaciónTexto completoActualización por claseCategoria DeCSCategoria DeCS explodidaCategoria CIE-10SubSetsPaís de AfiliaciónAfiliación
3	and or and not		PalabrasDescriptor de asuntoDescriptor de asunto primarioLímitesAutorPalabras del títuloPalabras del resumenIdiomaPaís de publicaciónNombre de substanciaNombre personal como asuntoRevistaAsunto de RevistaISSNTipo de publicaciónIdentificador únicoMes de ingresoAño de publicaciónTexto completoActualización por claseCategoria DeCSCategoria DeCS explodidaCategoria CIE-10SubSetsPaís de AfiliaciónAfiliación

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud